Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT6 | P42226 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 2/20 | 0.47 |
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.47 |
| ▸ | TTK | P33981 | 1/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.46 |
| ▸ | FLT4 | P35916 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | JAK2 | O60674 | 2/20 | 0.45 |
| ▸ | BRD4 | O60885 | 2/20 | 0.45 |
| ▸ | CSF1R | P07333 | 3/20 | 0.44 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1284620 | 0.91 | JAK3 (0.42) | STAT6JAK3MAP4K1TTKPTK2 | |
| SCHEMBL1284285 | 0.87 | CDK4 (0.51) | STAT6JAK3FLT4KDRJAK2 | |
| SCHEMBL1284832 | 0.87 | JAK3 (0.38) | STAT6JAK3FLT4KDRJAK2 | |
| SCHEMBL1285257 | 0.85 | PTK2 (0.43) | JAK3PTK2CSF1R | |
| SCHEMBL1285097 | 0.85 | JAK2 (0.38) | STAT6JAK3FLT4KDRJAK2 | |
| SCHEMBL1285380 | 0.84 | JAK3 (0.47) | JAK3FLT4KDRJAK2BRD4 | |
| SCHEMBL1284495 | 0.84 | JAK2 (0.38) | STAT6JAK3FLT4KDRJAK2 | |
| SCHEMBL1284416 | 0.83 | JAK3 (0.49) | JAK3FLT4KDRJAK2 | |
| SCHEMBL1285114 | 0.82 | JAK3 (0.45) | JAK3FLT4KDRJAK2BRD4 | |
| SCHEMBL1284506 | 0.82 | CAMK2D (0.43) | STAT6JAK3JAK2CSF1RTBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-04-12 | — | — | US | claimed |
| EP-2403853-A1 | PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS | Medical Research Council Technology (GB) | 2012-01-11 | — | — | EP | claimed |
| EP-2403853-A1 | PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS | Medical Research Council Technology (GB) | 2012-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MARK3, MAPK8, CDK8 | STAT6 446/4885JAK3 20/4885MAP4K1 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.